{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:51:49Z","timestamp":1794073909870,"version":"4.8.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Apollo Therapeutics Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alcohol use disorder (AUD) represents a tremendous societal burden, yet few efficacious therapies are available and widely used. Pre-clinical and human observational data support fibroblast growth factor 21 (FGF21) as a promising therapeutic target for the treatment of AUD. The objective of this study is to identify a robust genetic instrument for FGF21 agonism and leverage it to explore the effects of FGF21 agonism on AUD and related traits, as well as metabolic outcomes more widely.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We first compared associations with the positive control outcomes of liver fat and liver cirrhosis risk for the FGF21 cis-protein quantitative trait locus (cis-pQTL) (rs838131) to those for the common allele FGF21 L174P missense variant (rs739320). Having identified the L174P missense variant as a plausible genetic instrument, we subsequently performed association analyses investigating effects on AUD, related traits, and metabolic outcomes more widely. Finally, we performed colocalisation analyses to test whether observed association results reflect a causal mechanism that overlaps with the clinical effects of FGF21 on liver fat and liver cirrhosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Consistent association and colocalisation evidence support a protective association between genetically predicted FGF21 agonism and alcohol consumption (association\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091\u2009\u00d7\u200910\n                      <jats:sup>\u221218<\/jats:sup>\n                      , colocalisation posterior probability\u2009=\u20090.90), problematic alcohol use (association\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02, posterior probability\u2009=\u20090.64), and AUD (association\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20099\u2009\u00d7\u200910\n                      <jats:sup>\u22128<\/jats:sup>\n                      , posterior probability\u2009=\u20090.97). Similar evidence was also observed for favourable effects of FGF21 on improving kidney function, lowering triglyceride levels, lowering proportional energy intake from carbohydrates, increasing proportional energy intake from protein and fat, increasing body weight and lowering waist-to-hip ratio.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study identifies a genetic instrument for FGF21 effects to provide causal human evidence supporting favourable effects of FGF21 analogues for the treatment of AUD and related traits, as well as on metabolic outcomes more broadly. Further clinical study is duly warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04807-x","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:29:20Z","timestamp":1774247360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Robust human genetic evidence supporting causal effects of FGF21 on reducing alcohol consuming behaviours"],"prefix":"10.1186","volume":"24","author":[{"given":"H\u00e9l\u00e9ne T.","family":"Cronj\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sile","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Gurrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijana","family":"Vujkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna C.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipender","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"4807_CR1","doi-asserted-by":"publisher","first-page":"E292","DOI":"10.1152\/ajpendo.00101.2017","volume":"313","author":"T Xie","year":"2017","unstructured":"Xie T, Leung PS. Fibroblast growth factor 21: a regulator of metabolic disease and health span. Am J Physiol Endocrinol Metab. 2017;313:E292\u2013302.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4807_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.tem.2024.02.001","volume":"35","author":"ZSW Chui","year":"2024","unstructured":"Chui ZSW, Shen Q, Xu A. Current status and future perspectives of FGF21 analogues in clinical trials. Trends Endocrinol Metab. 2024;35:371\u201384.","journal-title":"Trends Endocrinol Metab"},{"key":"4807_CR3","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","volume":"29","author":"DL Bhatt","year":"2023","unstructured":"Bhatt DL, Bays HE, Miller M, Cain JE, Wasilewska K, Andrawis NS, et al. The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med. 2023;29:1782\u201392.","journal-title":"Nat Med"},{"key":"4807_CR4","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","volume":"392","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, et al. Efruxifermin in compensated liver cirrhosis caused by MASH. N Engl J Med. 2025;392:2413\u201324.","journal-title":"N Engl J Med"},{"key":"4807_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","volume":"29","author":"SA Kliewer","year":"2019","unstructured":"Kliewer SA, Mangelsdorf DJ. A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab. 2019;29:246\u201353.","journal-title":"Cell Metab"},{"key":"4807_CR6","doi-asserted-by":"crossref","unstructured":"Cooley BJ, Occelli Hanbury-Brown CV, Choi EA, Heller WA, Lim AW, Lawrence AJ, Haber PS, McNally GP, Millan EZ. FGF21 analogue PF-05231023 on alcohol consumption and neuronal activity in the nucleus accumbens. Neuropsychopharmacol.\u00a02026;51:519-29.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/40419727\/.","DOI":"10.1038\/s41386-025-02133-z"},{"key":"4807_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100578","volume":"3","author":"T Wang","year":"2022","unstructured":"Wang T, Farokhnia M, Leggio L. FGF21 regulates alcohol intake: new hopes on the rise for alcohol use disorder treatment? Cell Rep Med. 2022;3:100578.","journal-title":"Cell Rep Med"},{"key":"4807_CR8","unstructured":"World Health Organization. Global status report on alcohol and health and treatment of substance use disorders.Geneva: World Health Organization; 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240096745."},{"key":"4807_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jama.2020.2012","volume":"325","author":"AK Patel","year":"2021","unstructured":"Patel AK, Balasanova AA. Treatment of alcohol use disorder. JAMA. 2021;325:596.","journal-title":"JAMA"},{"key":"4807_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2021.100066","volume":"1","author":"ME Haas","year":"2021","unstructured":"Haas ME, Pirruccello JP, Friedman SN, Wang M, Emdin CA, Ajmera VH, et al. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genom. 2021;1:100066.","journal-title":"Cell Genom"},{"key":"4807_CR11","doi-asserted-by":"publisher","unstructured":"Vujkovic M, Kaplan DE, Ghouse J, Loza B-L, Brancale J, Lewis A, Zhang DY, Levin MG, Veatch OJ, Johnson JP, et al. Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways. Preprint at 2025\u00a0https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2025.09.16.25335186v1.","DOI":"10.1101\/2025.09.16.25335186v1"},{"key":"4807_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41588-024-01720-y","volume":"56","author":"J Ghouse","year":"2024","unstructured":"Ghouse J, Sveinbj\u00f6rnsson G, Vujkovic M, Seidelin A-S, Gellert-Kristensen H, Ahlberg G, et al. Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis. Nat Genet. 2024;56:827\u201337.","journal-title":"Nat Genet"},{"key":"4807_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK biobank. Nature. 2023;622:329\u201338.","journal-title":"Nature"},{"key":"4807_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41562-021-01182-w","volume":"6","author":"J Merino","year":"2022","unstructured":"Merino J, Dashti HS, Sarnowski C, Lane JM, Todorov PV, Udler MS, et al. Genetic analysis of dietary intake identifies new loci and functional links with metabolic traits. Nat Hum Behav. 2022;6:155\u201363.","journal-title":"Nat Hum Behav"},{"key":"4807_CR15","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1038\/s41591-023-02653-5","volume":"29","author":"H Zhou","year":"2023","unstructured":"Zhou H, Kember RL, Deak JD, Xu H, Toikumo S, Yuan K, et al. Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals. Nat Med. 2023;29:3184\u201392.","journal-title":"Nat Med"},{"key":"4807_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41586-022-05477-4","volume":"612","author":"GRB Saunders","year":"2022","unstructured":"Saunders GRB, Wang X, Chen F, Jang S-K, Liu M, Wang C, et al. Genetic diversity fuels gene discovery for tobacco and alcohol use. Nature. 2022;612:720\u20134.","journal-title":"Nature"},{"key":"4807_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipil\u00e4 TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508\u201318.","journal-title":"Nature"},{"key":"4807_CR18","unstructured":"Verma A, Huffman JE, Rodriguez A, Conery M, Liu M, Ho Y-L, Kim Y, Heise DA, Guare L, Panickan VA, et al. Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. Science. 2024;385:eadj1182."},{"key":"4807_CR19","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1038\/s41588-025-02335-7","volume":"57","author":"KJ Karczewski","year":"2025","unstructured":"Karczewski KJ, Gupta R, Kanai M, Lu W, Tsuo K, Wang Y, et al. Pan-UK biobank genome-wide association analyses enhance discovery and resolution of ancestry-enriched effects. Nat Genet. 2025;57:2408\u201317.","journal-title":"Nat Genet"},{"key":"4807_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/hmg\/ddy327","volume":"28","author":"SL Pulit","year":"2019","unstructured":"Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. Hum Mol Genet. 2019;28:166\u201374.","journal-title":"Hum Mol Genet"},{"key":"4807_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200785","volume":"13","author":"SK Kim","year":"2018","unstructured":"Kim SK. Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. PLoS One. 2018;13:e0200785.","journal-title":"PLoS One"},{"key":"4807_CR22","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41588-024-01714-w","volume":"56","author":"JM Keaton","year":"2024","unstructured":"Keaton JM, Kamali Z, Xie T, Vaez A, Williams A, Goleva SB, et al. Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits. Nat Genet. 2024;56:778\u201391.","journal-title":"Nat Genet"},{"key":"4807_CR23","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41467-022-29650-5","volume":"13","author":"S Said","year":"2022","unstructured":"Said S, Pazoki R, Karhunen V, V\u00f5sa U, Ligthart S, Bodinier B, et al. Genetic analysis of over half a million people characterises C-reactive protein loci. Nat Commun. 2022;13:2198.","journal-title":"Nat Commun"},{"key":"4807_CR24","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.cell.2020.06.045","volume":"182","author":"M-H Chen","year":"2020","unstructured":"Chen M-H, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. Cell. 2020;182:1198-1213.e14.","journal-title":"Cell"},{"key":"4807_CR25","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1038\/s41467-019-11576-0","volume":"10","author":"A Teumer","year":"2019","unstructured":"Teumer A, Li Y, Ghasemi S, Prins BP, Wuttke M, Hermle T, et al. Genome-wide association meta-analyses and fine-mapping elucidate pathways influencing albuminuria. Nat Commun. 2019;10:4130.","journal-title":"Nat Commun"},{"key":"4807_CR26","unstructured":"Liu H, Abedini A, Ha E, Ma Z, Sheng X, Dumoulin B, Qiu C, Aranyi T, Li S, Dittrich N, et al. Kidney multiome-based genetic scorecard reveals convergent coding and regulatory variants. Science. 2025;387:eadp4753."},{"key":"4807_CR27","doi-asserted-by":"crossref","unstructured":"Stanzick KJ, Li Y, Schlosser P, Gorski M, Wuttke M, Thomas LF, Rasheed H, Rowan BX, Graham SE, Vanderweff BR, et al. Discovery and prioritization of variants and genes for kidney function in >1.2 million individuals. Nat Commun. 2021;12:4350.","DOI":"10.1038\/s41467-021-24491-0"},{"key":"4807_CR28","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41588-019-0504-x","volume":"51","author":"A Tin","year":"2019","unstructured":"Tin A, Marten J, Halperin Kuhns VL, Li Y, Wuttke M, Kirsten H, et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat Genet. 2019;51:1459\u201374.","journal-title":"Nat Genet"},{"key":"4807_CR29","doi-asserted-by":"crossref","unstructured":"Graham SE, Clarke SL, Wu K-HH, Kanoni S, Zajac GJM, Ramdas S, Surakka I, Ntalla I, Vedantam S, Winkler TW, et al. The power of genetic diversity in genome-wide association studies of lipids. Nature. 2021;600:675\u2013679.","DOI":"10.1038\/s41586-021-04064-3"},{"key":"4807_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41586-025-09272-9","volume":"645","author":"K Carss","year":"2025","unstructured":"Carss K, Halldorsson BV, Hou L, Liu J, Wheeler E, Lo Y, et al. Whole-genome sequencing of 490,640 UK Biobank participants. Nature. 2025;645:692\u2013701.","journal-title":"Nature"},{"key":"4807_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155616","volume":"145","author":"A Giontella","year":"2023","unstructured":"Giontella A, Zagkos L, Geybels M, Larsson SC, Tzoulaki I, Mantzoros CS, et al. Renoprotective effects of genetically proxied fibroblast growth factor 21: Mendelian randomization, proteome-wide and metabolome-wide association study. Metabolism. 2023;145:155616.","journal-title":"Metabolism"},{"key":"4807_CR32","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","volume":"31","author":"MJ Machiela","year":"2015","unstructured":"Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31:3555\u20137.","journal-title":"Bioinformatics"},{"key":"4807_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008720","volume":"16","author":"C Wallace","year":"2020","unstructured":"Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet. 2020;16:e1008720.","journal-title":"PLoS Genet"},{"key":"4807_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383.","journal-title":"PLoS Genet"},{"key":"4807_CR35","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ng.210","volume":"40","author":"A Hazra","year":"2008","unstructured":"Hazra A, Kraft P, Selhub J, Giovannucci EL, Thomas G, Hoover RN, et al. Common variants of FUT2 are associated with plasma vitamin B12 levels. Nat Genet. 2008;40:1160\u20132.","journal-title":"Nat Genet"},{"key":"4807_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.cld.2024.06.006","volume":"28","author":"HY Choi","year":"2024","unstructured":"Choi HY, Balter DR, Haque LY. Epidemiology and Health care burden of alcohol use disorder. Clin Liver Dis. 2024;28:577\u201388.","journal-title":"Clin Liver Dis"},{"key":"4807_CR37","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters M, O\u2019Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacic K, et al. Pharmacotherapy for Alcohol Use disorder: a systematic review and meta-analysis. JAMA. 2023;330:1653\u201365.","journal-title":"JAMA"},{"key":"4807_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3340","volume":"7","author":"W Yaseen","year":"2024","unstructured":"Yaseen W, Mong J, Zipursky J. Sobering perspectives on the treatment of alcohol use disorder. JAMA Netw Open. 2024;7:e243340.","journal-title":"JAMA Netw Open"},{"key":"4807_CR39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","volume":"82","author":"CS Hendershot","year":"2025","unstructured":"Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiat. 2025;82:395\u2013405.","journal-title":"JAMA Psychiat"},{"key":"4807_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz9890","volume":"6","author":"CA Gilroy","year":"2020","unstructured":"Gilroy CA, Capozzi ME, Varanko AK, Tong J, D\u2019Alessio DA, Campbell JE, et al. Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia. Sci Adv. 2020;6:eaaz9890.","journal-title":"Sci Adv"},{"key":"4807_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103202","volume":"63","author":"Q Pan","year":"2021","unstructured":"Pan Q, Lin S, Li Y, Liu L, Li X, Gao X, et al. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine. 2021;63:103202.","journal-title":"EBioMedicine"},{"key":"4807_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03700-9","volume":"22","author":"D Gill","year":"2024","unstructured":"Gill D, Dib M-J, Cronj\u00e9 HT, Karhunen V, Woolf B, Gagnon E, et al. Common pitfalls in drug target Mendelian randomization and how to avoid them. BMC Med. 2024;22:473.","journal-title":"BMC Med"},{"key":"4807_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","volume":"18","author":"H Dowden","year":"2019","unstructured":"Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18:495\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"4807_CR44","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856\u201360.","journal-title":"Nat Genet"},{"key":"4807_CR45","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar S, Owen BM, Song P, Hernandez G, Zhang Y, Zhou Y, et al. FGF21 regulates sweet and alcohol preference. Cell Metab. 2016;23:344\u20139.","journal-title":"Cell Metab"},{"key":"4807_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","volume":"34","author":"KH Flippo","year":"2022","unstructured":"Flippo KH, Trammell SAJ, Gillum MP, Aklan I, Perez MB, Yavuz Y, et al. FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit. Cell Metab. 2022;34:317-328.e6.","journal-title":"Cell Metab"},{"key":"4807_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.alcohol.2024.08.001","volume":"121","author":"AR Lanng","year":"2024","unstructured":"Lanng AR, Gasbjerg LS, Sucksdorff AIF, Svenningsen JS, Vilsb\u00f8ll T, Gillum MP, et al. Alcohol-induced fibroblast growth factor 21 secretion is increased in individuals with alcohol use disorder. Alcohol. 2024;121:69\u201374.","journal-title":"Alcohol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04807-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04807-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04807-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:20:32Z","timestamp":1777512032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04807-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4807"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04807-x","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used summary data, for which ethical approval was obtained in the cited original studies.This study used summary data, and participant consent to participate was obtained in the cited original studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study only used summary data and consent for publication is therefore not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.G. is an Editorial Advisor at BMC Medicine. H.T.C., S.H. and D.G. are employees of Sequoia Genetics, a private research and development consultancy that works with investors, pharma and biotech in leveraging human genetic data to inform drug discovery and development. Sequoia Genetics received funding from Apollo Therapeutics to undertake this work. R.B., R.G. and R.M. are employees and shareholders of Apollo Therapeutics. D.G. is a Special Advisor to Apollo Therapeutics and has financial interests in several private biotechnology companies. M.V. and S.C.L. have no relevant disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}